Prognostic Value of MicroRNAs in Stage II Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
| Autor: | Chellan Kumarasamy, Siddharta Baxi, Sunil Krishnan, Ajay Gupta, Shanthi Sabarimurugan, Madurantakam Royam Madhav, Rama Jayaraj |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty MEDLINE Subgroup analysis 03 medical and health sciences Genetic Heterogeneity 0302 clinical medicine Sex Factors Internal medicine Genetics medicine Biomarkers Tumor Humans Neoplasm Staging Proportional Hazards Models Pharmacology business.industry Hazard ratio Computational Biology General Medicine Random effects model Prognosis Confidence interval Human genetics MicroRNAs 030104 developmental biology Systematic review Gene Expression Regulation 030220 oncology & carcinogenesis Meta-analysis Molecular Medicine business Colorectal Neoplasms Publication Bias |
| Zdroj: | Molecular diagnosistherapy. 24(1) |
| ISSN: | 1179-2000 |
| Popis: | We performed a systematic review and meta-analysis to identify and underline multiple microRNAs (miRNAs) as biomarkers of disease prognosis in stage II colorectal cancer (CRC) patients. This systematic review and meta-analysis study was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The required articles were collected from online bibliographic databases from January 2011 to November 2019 with multiple permutation keywords. Quantitative data synthesis was based on a meta-analysis with pooled data to observe and analyse the outcome measures and effect estimates by using the random effect model. The subgroup analysis was performed from demographic characteristics and the available data. Eighteen articles were included in this study, 16 of which were incorporated for meta-analysis to examine the stage II CRC prognosis with up- and downregulated miRNA expressions. The pooled hazard ratio (HR) for death in stage II CRC patients was 1.90 (95% confidence interval 1.63–2.211), with a significant p value. A subgroup analysis based on up- or downregulated miRNA expression individually and any deregulated miRNA was also associated with a worse prognosis. The subgroup analysis included parameters such as age, gender, stage II and III combined patients’ survival and the repetitive miRNAs (miR21, miR215, miR143-5p, miR106a and miR145) individually. MicroRNAs play a significant role in determining prognosis in stage II CRC patients, with upregulation of miR21, miR215, miR143-5p and miR106a, in particular, portending a worse prognosis. These miRNAs could be considered for further evaluation as biomarkers of prognosis and to guide the decision to administer adjuvant chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink